Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today issued the following letter to shareholders from the Company’s Chief Executive Officer.Dear Shareholders, As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therapeutics throu ...